Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Accepted: 23 April 2022
First Online: 17 May 2022
Declarations
:
: KS reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Gruenenthal, Stada, Lucher Pharma, Biogen, BIAL, and AbbVie, and honoraria from the International Parkinson and Movement Disorders Society. All other authors declare no competing interests.